1. Putting Evidence Into Practice: Highlights From Toronto

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Entrectinib in Locally Advanced or Metastatic ROS1-Positive NSCLC

4. TRIDENT-1: Repotrectinib in ROS1-Positive NSCLC

5. ALTA-1L: Brigatinib vs Crizotinib in ALK TKI-Naive ALK-Positive NSCLC

6. Long-Term Results From Erlotinib + Atezolizumab in Advanced NSCLC

7. PD-L1 Expression From FLAURA

8. Putting Evidence Into Practice: Highlights From Toronto

9. Poziotinib for EGFR Exon 20 Mutant NSCLC

10. Poziotinib for HER2 Exon 20 Mutant NSCLC

11. VISION: Tepotinib for MET Exon 14 Skipping Mutant NSCLC

12. PROFILE 1001: Crizotinib in MET Exon 14 Skipping Mutant NSCLC

13. LIBRETTO-001: LOXO-292 in RET-Positive NSCLC

14. Osimertinib + BLU-667 in EGFR-Mutated NSCLC With Acquired RET Rearrangement

15. Putting Evidence Into Practice: Highlights From Toronto

16. LUME-Meso: Nintedanib + Pemetrexed/Cisplatin in Unresectable MPM

17. Ganetespib + Pemetrexed + Cisplatin or Carboplatin for Pleural Mesothelioma

18. ALTER 1202: Anlotinib as Third-Line or Beyond for Relapsed SCLC

19. Lurbinectedin + Doxorubicin in Relapsed SCLC

20. Putting Evidence Into Practice: Highlights From Toronto

21. IMpower132: First-Line Atezolizumab + Carboplatin/Cisplatin + Pemetrexed

22. JAVELIN Lung 200: Avelumab vs Docetaxel in Previously Treated NSCLC

23. Pembrolizumab for Oligometastatic NSCLC After Locally Ablative Therapy

24. NELSON: Lung Cancer Screening Trial

25. NELSON: Mortality Rates by Gender

26. Putting Evidence Into Practice: Highlights From Toronto

27. MERIT: Long-Term Nivolumab in MPM

28. DREAM: Durvalumab + Chemotherapy as First-Line Therapy for MPM

29. Pembrolizumab in Previously Treated MM

30. IMpower133: Atezolizumab + Carboplatin + Etoposide in ES-SCLC

31. Putting Evidence Into Practice: Highlights From Toronto

32. PACIFIC: OS Data

33. PACIFIC: OS Subgroups

34. Hoosier Cancer Research Network LUN 14-179: Consolidation Pembrolizumab

35. DETERRED: Concurrent Atezolizumab

36. DETERRED: Safety Data

37. Cross-Trial Comparison

38. Abbreviations

39. Abbreviations (cont)

40. Abbreviations (cont)